Buscar
Transcode Therapeutics Inc
RNAZAñadir a la lista de seguimiento
7.440USD
+1.230+19.81%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
6.82MCap. mercado
PérdidaP/E TTM
Más Datos de Transcode Therapeutics Inc Compañía
TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. It is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The Company is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.
Información de Transcode Therapeutics Inc
Símbolo de cotizaciónRNAZ
Nombre de la empresaTranscode Therapeutics Inc
Fecha de salida a bolsaApr 28, 2021
Director ejecutivoCalais (Philippe P)
Número de empleados7
Tipo de seguridadOrdinary Share
Fin del año fiscalApr 28
Dirección6 Liberty Square
CiudadBOSTON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02109
Teléfono18573016857
Sitio Webhttps://www.transcodetherapeutics.com/
Símbolo de cotizaciónRNAZ
Fecha de salida a bolsaApr 28, 2021
Director ejecutivoCalais (Philippe P)
Ejecutivos de Transcode Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Thomas A. (Tom) Fitzgerald
Mr. Thomas A. (Tom) Fitzgerald
Chief Financial Officer, Vice President, Director
Chief Financial Officer, Vice President, Director
3.00
--
Dr. Philippe P. Calais, Ph.D.
Dr. Philippe P. Calais, Ph.D.
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
2.00
--
Dr. Erik Manting, Ph.D.
Dr. Erik Manting, Ph.D.
Independent Director
Independent Director
--
--
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
--
--
Dr. Daniel Vlock
Dr. Daniel Vlock
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Elizabeth Czerepak
Ms. Elizabeth Czerepak
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Thomas A. (Tom) Fitzgerald
Mr. Thomas A. (Tom) Fitzgerald
Chief Financial Officer, Vice President, Director
Chief Financial Officer, Vice President, Director
3.00
--
Dr. Philippe P. Calais, Ph.D.
Dr. Philippe P. Calais, Ph.D.
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
2.00
--
Dr. Erik Manting, Ph.D.
Dr. Erik Manting, Ph.D.
Independent Director
Independent Director
--
--
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
--
--
Dr. Daniel Vlock
Dr. Daniel Vlock
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Elizabeth Czerepak
Ms. Elizabeth Czerepak
Independent Director
Independent Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Transcode Therapeutics Inc?
Los cinco principales accionistas de Transcode Therapeutics Inc son: Mr. Thomas A. (Tom) Fitzgerald
¿Cuántas instituciones poseen acciones de Transcode Therapeutics Inc (RNAZ)?
A fecha de 2026Q1, 37 instituciones poseen acciones de Transcode Therapeutics Inc, con un valor de mercado combinado de aproximadamente 77.85K, lo que representa el 8.49% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -42306.00.